iRadimed (IRMD)
(Delayed Data from NSDQ)
$66.17 USD
+7.83 (13.42%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $66.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IRMD 66.17 +7.83(13.42%)
Will IRMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRMD
iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates
Integer (ITGR) Q2 Earnings Lag Estimates
IRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for June 12th
IRadimed (IRMD) Lags Q1 Earnings Estimates
Integer (ITGR) Beats Q1 Earnings and Revenue Estimates
Other News for IRMD
Iradimed outlines $100M revenue run-rate for 2026 driven by new 3870 pump launch
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
IRMD Projects FY25 Revenue Growth to Reach Up to $82.5 Million
IRMD Anticipates Solid Q3 Revenue Growth
Iradimed (IRMD) Achieves Record Q2 Revenue with Strong Growth Prospects